Acid-sensitive PEGylated paclitaxel prodrug nanoparticles for cancer therapy: Effect of PEG length on antitumor efficacy

Mu, Jingqing; Zhong, Haiping; Zou, Hui; Liu, Tao; Yu, Na; Zhang, Xi; Xu, Zunkai; Chen, Ziqi; Guo, Shutao

doi:10.1016/j.jconrel.2020.07.022

Cited by 51 publications

(33 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anticancer efficacy of the lipophilic anticancer drug PTX has been limited because it is difficult to control its release rate and ensure the completion of its release profile from the hydrophobic part of the carriers, as it has previously been reported [ 36 , 37 ]. Therefore, PTX@TNPs with different loading contents (50 and 180 wt% of PTX) were compared to assess the enhanced anticancer efficacy against p-gp-overexpressing HCT 15 cells under different solubilization and controlled PTX release conditions.…”

Section: Resultsmentioning

confidence: 99%

High Solubilization and Controlled Release of Paclitaxel Using Thermosponge Nanoparticles for Effective Cancer Therapy

Lee

Sung

et al. 2021

Pharmaceutics

View full text Add to dashboard Cite

Cancer, which is a leading cause of death, contributes significantly to reducing life expectancy worldwide. Even though paclitaxel (PTX) is known as one of the main anticancer drugs, it has several limitations, including low solubility in aqueous solutions, a limited dosage range, an insufficient release amount, and patient resistance. To overcome these limitations, we suggest the development of PTX-loaded thermosponge nanoparticles (PTX@TNP), which result in improved anticancer effects, via a simple nanoprecipitation method, which allows the preparation of PTX@TNPs with hydrophobic interactions without any chemical conjugation. Further, to improve the drug content and yield of the prepared complex, the co-organic solvent ratio was optimized. Thus, it was observed that the drug release rate increased as the drug capacity of PTX@TNPs increased. Furthermore, increasing PTX loading led to considerable anticancer activity against multidrug resistance (MDR)-related colorectal cancer cells (HCT 15), implying a synergistic anticancer effect. These results suggest that the solubilization of high drug amounts and the controlled release of poorly water-soluble PTX using TNPs could significantly improve its anticancer therapy, particularly in the treatment of MDR-p-glycoprotein-overexpressing cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

High Solubilization and Controlled Release of Paclitaxel Using Thermosponge Nanoparticles for Effective Cancer Therapy

Lee

Sung

et al. 2021

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“… 73 Mu and co-workers reported pH-sensitive polymeric paclitaxel (PTX) prodrugs (named PKPs) for ovarian cancer therapy ( Table 1 ). 74 As shown in Fig. 4A , in order to synthesize PKPs, the intermediate compound 2 containing acrylate groups was synthesized by linking PTX with compound 1 via the acid-sensitive acetone-based acyclic ketal linker ( Table 2 ).…”

Section: Ph-responsive Nanoassembliesmentioning

confidence: 99%

Stimulus-responsive self-assembled prodrugs in cancer therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This self-assembled prodrug has excellent stability with drug loading up to 60.3% ( Huang et al, 2018 ). Acyclic ketals are generally more acid-sensitive than acetals, so the development of pH-sensitive polymeric prodrug micelles based on acyclic ketal–coupled linkers are more desirable ( Mu et al, 2020 ). Guo et al constructed acyclic-ketal–based acid-sensitive PTX prodrug micelles using PEG with different lengths.…”

Section: Ph-sensitive Polymer-ptx Prodrugmentioning

confidence: 99%

“…Guo et al constructed acyclic-ketal–based acid-sensitive PTX prodrug micelles using PEG with different lengths. They found that the length of PEG affects the hydrolysis kinetics, pharmacokinetics, biodistribution, and antitumor activity of the prodrug nanoparticles ( Mu et al, 2020 ).…”

Section: Ph-sensitive Polymer-ptx Prodrugmentioning

confidence: 99%

Recent Advances in Stimuli-Sensitive Amphiphilic Polymer-Paclitaxel Prodrugs

Zhou

Wen

Wang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Paclitaxel (PTX) is a broad-spectrum chemotherapy drug employed in the treatment of a variety of tumors. However, the clinical applications of PTX are limited by its poor water solubility. Adjuvants are widely used to overcome this issue. However, these adjuvants often have side effects and poor biodistribution. The smart drug delivery system is a promising strategy for the improvement of solubility, permeability, and stability of drugs, and can promote sustained controlled release, increasing therapeutic efficacy and reducing side effects. Polymeric prodrugs show great advantages for drug delivery due to their high drug loading and stability. There has been some groundbreaking work in the development of PTX-based stimulus-sensitive polymeric prodrug micelles, which is summarized in this study. We consider these in terms of the four main types of stimulus (pH, reduction, enzyme, and reactive oxygen species (ROS)). The design, synthesis, and biomedical applications of stimulus-responsive polymeric prodrugs of PTX are reviewed, and the current research results and future directions of the field are summarized.

show abstract

Acid-sensitive PEGylated paclitaxel prodrug nanoparticles for cancer therapy: Effect of PEG length on antitumor efficacy

Cited by 51 publications

References 40 publications

High Solubilization and Controlled Release of Paclitaxel Using Thermosponge Nanoparticles for Effective Cancer Therapy

High Solubilization and Controlled Release of Paclitaxel Using Thermosponge Nanoparticles for Effective Cancer Therapy

Stimulus-responsive self-assembled prodrugs in cancer therapy

Recent Advances in Stimuli-Sensitive Amphiphilic Polymer-Paclitaxel Prodrugs

Contact Info

Product

Resources

About